TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05938114

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bonalive
Description: Bonalive® is a bioactive glass synthetic bone substitute material that has been shown to have a low substitution rate and antibacterial properties. It has been used successfully in the orthopaedics, craniofacial and ear nose and throat (ENT) specialities for the treatment of osteomyelitis, sinusitis and bony cyst cavities. There have also been a few maxillofacial surgery case reports on its usage in the jaws.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bio-Oss®
Description: Bio-Oss® is a bovine xenogeneic bone graft substitute that is widely used in regenerative dentistry. Bio-Oss® is very similar to human bone in its structure and chemical make-up. The material's porosity allows for vascularisation and new bone formation.
Study: NCT05009017

Intervention type: DRUG
Intervention: Bevacizumab
Description: Patients with colorectal cancer or lung cancer who use originator or biosimilar of bevacizumab

Intervention type: DRUG
Intervention: Bevacizumab
Description: Patients with colorectal cancer or lung cancer who use originator or biosimilar of bevacizumab
Study: NCT05719935

Intervention type: DEVICE
Intervention: KinematX total wrist arthroplasty system
Description: The KinematX total wrist implant is a joint metal/polymer semi-constrained cemented prosthesis that utilizes an articulation that mimics the midcarpal joint instead of the radiocarpal joint.
Study: NCT06333418

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Glasses Group
Description: Before the colonoscopy procedure, 360-degree VR video scenes will be watched to patients 30 minutes using VR head device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glass waterfall
Description: Before the colonoscopy procedure, patients will watch and listen 30 minutes a portative glass waterfall
Study: NCT05259527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergocalciferol Capsules
Description: Vitamin D2 50,000IU by mouth once weekly for 8 weeks then once per month thereafter.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol Capsules
Description: Vitamin D3 5,000IU by mouth daily
Study: NCT06581900

Intervention type: OTHER
Intervention: Vitamin B12
Description: Quantification of Vitamin B12
Study: NCT05365802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPi-46
Description: Radiopharmaceutical will be administered via IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: As part of PET/CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: As part of PET/CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High Resolution Computed Tomography
Description: Will be conducted immediately after FAPI PET/CT
Study: NCT05588700

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity recommendations
Description: At the baseline, all participants will receive the international recommendations in terms of physical activity for promoting health in the general population.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity recommendations
Description: At the baseline, all participants will receive the international recommendations in terms of physical activity for promoting health in the general population.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Connected activity tracker
Description: At baseline, all participants will receive a connected activity tracker to wear 24 hours a day during one year. Patients will be asked to download an application, dedicated to the study so that the physical activity data (ie. number of steps per day) will be synchronized in the application.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connected activity tracker
Description: At baseline, all participants will receive a connected activity tracker to wear 24 hours a day during one year. Patients will be asked to download an application, dedicated to the study so that the physical activity data (ie. number of steps per day) will be synchronized in the application.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) Intervention
Description: The intervention will last 1 year and will have 2 phases. Phase 1: At each cycle of chemotherapy, patients will be proposed to perform 2-4 sessions per week. This program will be individual, supervised, performed at a moderate intensity. Between cycles, patients will be asked to perform 1-2 supervised collective live online physical activity sessions per week, proposed by a partner specialized in online PA.~Phase 2: After chemotherapy, patients will be asked to perform 2-3 PA sessions per week at a moderate intensity. Patients will be offered 2 options of PA practice: in the supervised collective live online PA session (as already performed in the phase 1), and/or in a fitness center (this practice will take place in a classic environment with a 9-month free access for patients thanks to a partnership).~In addition, patients will benefit from 4 individual motivational interviews, conducted by videoconference and/or by phone call with a professional.
Study: NCT04894370

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sample collection
Description: PBMC collection at baseline, after radiotherapy 8 Gy (gray), at 6 months and at 12 months from inclusion: 6 EDTA tubes of 6 ml of peripheral blood mononuclear cell \[PBMC\] will be sent to the central laboratory (Biomonitoring Platform of Besançon, CHRU de Besançon located at Etablissement Français du Sang) at room temperature within 24 hours via an approved carrier for their processing, storage and immunomonitoring analysis. A sending sheet of the samples will be attached to each single sample.~Plasma collection at baseline, after radiotherapy 8 Gy, at 6 months and at 12 months from inclusion: One 6 ml EDTA tube should be frozen in each investigation center for plasma collection.~Plasma for circulating tumoral DNA (ctDNA) collection at baseline, at 2, 6 and 12 months from inclusion: two EDTA tube of 4 ml should be frozen in each investigation center for ctDNA collection.
Study: NCT05369858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] SKLB1028
Description: A single 150 mg oral dose of \[14C\] SKLB1028 containing approximately 120 microcurie of \[14C\] SKLB1028
Study: NCT06105385

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suboccipital Myofascial Release Technique
Description: With the patient in a supine position, the therapist sits behind the patient with his or her forearms on the treatment table. The therapist places his fingers between the occiput and axis, with his fingers in semi-flexion (2nd, 3rd and 4th fingers), and continues to hold his hands on the occiput until relaxation is achieved in the suboccipital muscles. A light traction is applied at the end of the technique. Average application time is 4-5 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suboccipital Myofascial Release Technique
Description: With the patient in a supine position, the therapist sits behind the patient with his or her forearms on the treatment table. The therapist places his fingers between the occiput and axis, with his fingers in semi-flexion (2nd, 3rd and 4th fingers), and continues to hold his hands on the occiput until relaxation is achieved in the suboccipital muscles. A light traction is applied at the end of the technique. Average application time is 4-5 minutes.
Study: NCT05102188

Intervention type: COMBINATION_PRODUCT
Intervention: Assessment of sleep and related factors
Description: Eligible participants will be invited to fill out several forms and wear a watch-like device on their wrist (an accelerometer) for 7 days to assess their sleep habits. They will also be asked to sleep at home with a watch-like device attached to a sleeve which covers their index finger (an oximeter) for one night to assess whether they may have a sleep problem like sleep apnea.
Study: NCT05949190

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: M-RUSF+ (Maternal Ready-to-Use Supplementary Food + DHA/EPA/choline)
Description: Balanced energy protein supplement with added DHA/EPA/choline, micronutrients

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: M-RUSF+ (Maternal Ready-to-Use Supplementary Food + DHA/EPA/choline)
Description: Balanced energy protein supplement with added DHA/EPA/choline, micronutrients

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: M-RUSF (Maternal Ready-to-Use Supplementary Food)
Description: Balanced energy protein supplement with added micronutrients

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: M-RUSF (Maternal Ready-to-Use Supplementary Food)
Description: Balanced energy protein supplement with added micronutrients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: 1g dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: 1g dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: 1g dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: 1g dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: 400mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: 400mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: 400mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: 400mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfadoxine pyrimethamine
Description: Monthly, 1,500/75mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfadoxine pyrimethamine
Description: Monthly, 1,500/75mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfadoxine pyrimethamine
Description: Monthly, 1,500/75mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfadoxine pyrimethamine
Description: Monthly, 1,500/75mg dose

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: Novel program developed for illiterate end-users

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: Novel program developed for illiterate end-users

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insecticide-treated mosquito net
Description: Bed net to prevent malaria

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insecticide-treated mosquito net
Description: Bed net to prevent malaria

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insecticide-treated mosquito net
Description: Bed net to prevent malaria

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insecticide-treated mosquito net
Description: Bed net to prevent malaria
Study: NCT06526663

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: vignette exposure
Description: Participants will be randomized to be exposed to one of 16 written vignettes that vary four elements of the primary care experience. The four attributes can take two levels.~In the second round, individuals will be randomized to only 4 different vignettes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: vignette exposure
Description: Participants will be randomized to be exposed to one of 16 written vignettes that vary four elements of the primary care experience. The four attributes can take two levels.~In the second round, individuals will be randomized to only 4 different vignettes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: vignette exposure
Description: Participants will be randomized to be exposed to one of 16 written vignettes that vary four elements of the primary care experience. The four attributes can take two levels.~In the second round, individuals will be randomized to only 4 different vignettes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: vignette exposure
Description: Participants will be randomized to be exposed to one of 16 written vignettes that vary four elements of the primary care experience. The four attributes can take two levels.~In the second round, individuals will be randomized to only 4 different vignettes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: vignette exposure
Description: Participants will be randomized to be exposed to one of 16 written vignettes that vary four elements of the primary care experience. The four attributes can take two levels.~In the second round, individuals will be randomized to only 4 different vignettes.
Study: NCT05443802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin 0.05 IU/kg/h
Description: In the experimental arm, the patients will be given an insulin dose of 0.05 IU/kg/h.
Study: NCT05889832

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: measurement of physiological parameters wih Shen.AI Vitals software on various camera-equipped devices (smartphones, tablets, laptops)
Description: Resting heart rate (HR), heart rate variability (HRV) and breathing rate (BR) will be measured (estimated) with the use of remote photoplethysmography (1-minute face video analysis with Shen.AI Vitals software).~Reference measurements will be taken simultaneously (chest ECG for the calculation of HR and HRV; impedance pneumography for BR).
Study: NCT06430606

Intervention type: PROCEDURE
Intervention: Tint Time
Description: Arterial blood gas was obtained immediately after intubation(Tint) in supine position. Ventilator parameters and hemodynamic parameters were recorded.
Study: NCT05443802

Intervention type: DRUG
Group type: OTHER
Intervention: Insulin 0.10 IU/kg/h
Description: In the control arm, patients will receive an insulin dose of 0.10 IU/kg/h.
Study: NCT06430606

Intervention type: PROCEDURE
Intervention: T0 Time
Description: Arterial blood gas was obtained immediately after pneumoperitoneum in trendelenburg position. Ventilator parameters and hemodynamic parameters were recorded.

Intervention type: PROCEDURE
Intervention: T1
Description: Arterial blood gas was obtained immediately after pneumoperitoneum in trendelenburg position. Ventilator parameters and hemodynamic parameters were recorded.
Study: NCT04839627

Intervention type: OTHER
Intervention: serum progesterone measurement
Description: progesterone levels measurement on the day of the embryo transfer on all AMP cycles
Study: NCT05351970

Intervention type: PROCEDURE
Intervention: Barbed
Description: Efficacy of barbed and monofilament closure regarding incisional hernia
Study: NCT05364554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77242113
Description: JNJ-77242113 tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77242113
Description: JNJ-77242113 tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77242113
Description: JNJ-77242113 tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77242113
Description: JNJ-77242113 tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77242113
Description: JNJ-77242113 tablet will be administered orally.
Study: NCT05499468

Intervention type: OTHER
Group type: OTHER
Intervention: Popular-Opinion Leader-led encouragement during training meetings and informal conversation
Description: Investigators adapted evidence-based principles from the Popular Opinion Leader framework to increase utilizations of existing one-on-one emotional support resources for physicians-in-training at Stanford (an effective HIV prevention intervention developed by the CDC for changing social norms and reducing behavioral risk factors led by influential members of a community, trained to promote behavior change). All intervention activities designed to encourage utilization were delivered as part of health promotion during pre-existing clinical training meetings and no data was collected during these workshops. Identified POLs were recruited and trained to encourage their colleagues to use existing support resources and engage in two 30-60 minute workshops scheduled to occur during training meetings.
Study: NCT04619732

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Monitoring biochemical concentrations during cold machine perfusion
Description: Three microdialysis probes will be introduced into the kidney tissues, the vein and ureter in order to measure creatinine, glucose and lactate while the organ is undergoing cold perfusion prior to transplantation.
Study: NCT05364554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77242113
Description: JNJ-77242113 tablet will be administered orally.
Study: NCT04834635

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FundoRingOAGB
Description: laparoscopic one anastomosis gastric bypass with the total wrapping of the fundus of gastric excluded part and with suture cruroplasty if present hiatal hernia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OAGB
Description: laparoscopic one anastomosis gastric bypass with suture cruroplasty if present hiatal hernia
Study: NCT04550741

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telerehabilitation
Description: After obtaining consent, the volunteers will be included in the study at the start of the 4th week and randomized into two arms: Experimental and Control group
Study: NCT06367933

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mini-invasive spine surgery
Description: spine deformity correction using a mini-invasive technique
Study: NCT04569227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC-18
Description: 2000 mg PO daily
Study: NCT06241183

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Famotidine
Description: Patients in this group will receive 20mg IV Famotidine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Maalox/ Mylanta
Description: Patients in this group will receive 30 ml Maalox/ Mylanta.
Study: NCT04989023

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood flow restriction (BFR) with low load resistance training
Description: Combination of low load resistance exercise in the upper or lower limb with the addition of blood flow restriction or sham-blood flow restriction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood flow restriction (BFR) with low load resistance training
Description: Combination of low load resistance exercise in the upper or lower limb with the addition of blood flow restriction or sham-blood flow restriction.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Blood flow restriction (BFR) with low load resistance training
Description: Combination of low load resistance exercise in the upper or lower limb with the addition of blood flow restriction or sham-blood flow restriction.
Study: NCT04569227

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PO daily
Study: NCT04989023

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Blood flow restriction (BFR) with low load resistance training
Description: Combination of low load resistance exercise in the upper or lower limb with the addition of blood flow restriction or sham-blood flow restriction.
Study: NCT06305910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment with CD200AR-L
Description: Treatment with CD200AR-L (up to 3 dose levels of CD200AR-L with a Dose Level -1 in the event of toxicity) with fixed doses of GBM6-AD vaccine. Each patient will also be given topical imiquimod and a single dose of 300cGy re-irradiation.
Study: NCT06483698

Intervention type: OTHER
Intervention: Sublobar resection
Description: Sublobar resection is a series of surgical approaches for lung cancer.

Intervention type: OTHER
Intervention: Lobectomy
Description: Lobectomy is the surgical approach for lung cancer.
Study: NCT05034237

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ND;YAG 1064NM LASER
Description: laser hair removal sessions
Study: NCT06209268

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paricalcitol injection
Description: 5 μg intravenous paricalcitol (1 mL) per day in five consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% NaCl 1 ml per day in five consecutive days
Study: NCT06151821

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided meditation
Description: Meditation with guidance
Study: NCT06520046

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: Propioceptive exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Usual exercises
Study: NCT06443138

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized pre-habilitation program
Description: Each patient will undergo 4 weeks of individualized pre-habilitation before surgery.~Each session (1 session per day) will be carried out autonomously by the patient at home, via a dedicated application (Activiti Pro) installed on their tablet or smartphone.
Study: NCT05121129

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTBS
Description: 25 active iTBS sessions (5 sessions of 9.5 minutes/day, 1,800 pulses per session, 90% of resting motor threshold, placed over the left DLPFC)
Study: NCT04652609

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRESIONA
Description: Aerobic and strength exercise combined with restricction blood flow cuffs during chemotherapy treatment
Study: NCT04797026

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Letters to increase social connection with goal to alleviate loneliness
Description: Our hypothesis is that a social program connecting patients in residential care facilities with high school students through monthly letter writing would positively impact quality of life for both, reducing quantitative and qualitiative measures of loneliness
Study: NCT06488534

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Fermentable Oligo-, Di- Monosaccharides And Polyols (FODMAPs)
Description: A FODMAP solution of 200 mL will be infused in the colon for over 20 min. via the lumen of the solid-state catheter for high-resolution colonic manometry.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Fermentable Oligo-, Di- Monosaccharides And Polyols (FODMAPs)
Description: A FODMAP solution of 200 mL will be infused in the colon for over 20 min. via the lumen of the solid-state catheter for high-resolution colonic manometry.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Fermentable Oligo-, Di- Monosaccharides And Polyols (FODMAPs)
Description: A FODMAP solution of 200 mL will be infused in the colon for over 20 min. via the lumen of the solid-state catheter for high-resolution colonic manometry.
Study: NCT04849871

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Accelerated Partial Breast Irradiation
Description: APBI simulation must take place no more than 8 weeks from final definitive breast surgery.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Accelerated Partial Breast Irradiation
Description: APBI simulation must take place no more than 8 weeks from final definitive breast surgery.